

FAX**To** 1626**Company** USPTO**Fax** 703-872-9306**From** Julie D. McFalls**Tel** 919-483-1545 **Fax** 919-483-7988**E-mail** Julie.D.McFalls@gsk.com**Date** April 27, 2004 **Pages including cover** 6**Subject** Serial No.: 10/637,190

Filing Date: August 8, 2003



GlaxoSmithKline

Glaxo Wellcome Inc.
PO Box 13398
Five Moore Drive
Research Triangle Park
North Carolina 27709Tel: 919 483 2100
www.gsk.com**RECEIVED**
CENTRAL FAX CENTER

APR 27 2004

OFFICIAL

Attached:

Amendment and Response
Certificate of Transmission

The information contained in these documents is confidential and may also be privileged and is intended for the exclusive use of the addressee designated above. If you are not the intended recipient or the employee or agent responsible to deliver it to the intended recipient, any disclosure, reproduction, distribution, or any other dissemination or use of this communication is strictly prohibited. If you have received this transmission in error please contact us immediately by telephone so that we can arrange for its return.

CERTIFICATE OF TRANSMISSION BY FACSIMILE (37 CFR 1.8)			Docket No. PU3616US2
Applicant(s): HAFFNER et al.			
Serial No. 10/637,190	Filing Date August 8, 2003	Examiner Anderson, Rebecca L	Group Art Unit 1626
Invention: Use of FXR Ligands			
<p>I hereby certify that this <u>Amendment and Response</u> (Identify type of correspondence)</p> <p>is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. <u>703 872 9306</u>)</p> <p>on <u>April 27, 2004</u> (Date)</p> <p><u>Julie D. McFalls</u> (Typed or Printed Name of Person Signing Certificate)</p> <p><u>Julie D. McFalls</u> (Signature)</p>			
<p>Note: Each paper must have its own certificate of mailing.</p>			

P18/REV01

APR. 27. 2004 9:48AM

GLAXO WELLCOME

NO. 3428 P. 3

PU3616US2

RECEIVED
CENTRAL FAX CENTER

APR 26 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

OFFICIAL

In re Application of: HAFFNER, et al.
U.S. Ser. No.: 10/637,190
Filing Date.: August 8, 2003
Art Unit: 1626
Examiner: Anderson, Rebecca L
Title: Use of FXR Ligands

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

AMENDMENT and RESPONSE

This paper is submitted in response to the Office Action mailed 16 April 2004 for which a one month shortened statutory period to respond was set. Accordingly, this paper is timely filed on or before 16 May 2004.